Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 4.2 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 12.6 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspire pharma ltd - ivabradine hydrochloride - tablet - 5mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspire pharma ltd - ivabradine hydrochloride - tablet - 7.5mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspire pharma ltd - ivabradine hydrochloride - tablet - 2.5mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - ivabradine hydrochloride - tablet - 7.5mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - ivabradine hydrochloride - tablet - 5mg

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ivabradine hydrochloride, quantity: 8.085 mg (equivalent: ivabradine, qty 7.5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maize starch; maltodextrin; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000 - treatment of chronic stable angina symptomatic treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm and heart rate at or above 70 bpm, who are unable to tolerate or have a contraindication to the use of beta-blockers.,treatment of chronic heart failure treatment of symptomatic chronic heart failure of nyha classes ii or iii and with documented left ventricular ejection fraction (lvef) ? 35% in adult patients in sinus rhythm and with heart rate at or above 77 bpm, in combination with optimal standard chronic heart failure treatment.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ivabradine hydrochloride, quantity: 5.39 mg (equivalent: ivabradine, qty 5 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; maltodextrin; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000 - treatment of chronic stable angina symptomatic treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm and heart rate at or above 70 bpm, who are unable to tolerate or have a contraindication to the use of beta-blockers.,treatment of chronic heart failure treatment of symptomatic chronic heart failure of nyha classes ii or iii and with documented left ventricular ejection fraction (lvef) ? 35% in adult patients in sinus rhythm and with heart rate at or above 77 bpm, in combination with optimal standard chronic heart failure treatment.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - ivabradine hydrochloride, quantity: 5.39 mg (equivalent: ivabradine, qty 5 mg) - tablet, film coated - excipient ingredients: maltodextrin; lactose monohydrate; colloidal anhydrous silica; maize starch; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000 - treatment of chronic stable angina symptomatic treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm and heart rate at or above 70 bpm, who are unable to tolerate or have a contraindication to the use of beta-blockers, or in combination with atenolol 50mg once daily when angina is inadequately controlled.,treatment of chronic heart failure treatment of symptomatic chronic heart failure of nyha classes ii or iii and with documented left ventricular ejection fraction (lvef) ? 35% in adult patients in sinus rhythm and with heart rate at or above 77 bpm, in combination with optimal standard chronic heart failure treatment.